Patents by Inventor Xuqing Zhang

Xuqing Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Account Identifier Digitization Abstraction
    Publication number: 20180068302
    Abstract: Described herein are various technologies pertaining to integrating account identifier (e.g., card provider(s)) into a digitization system, for example, without requiring changes to a client application on a user device (e.g., smart phone). An extensible account identifier abstraction system is provided that stores data according to a unified data model and is accessible to the user device via unified interface(s). The extensible abstraction system includes one or more plugin modules/provider relay plugin(s) that convert call(s) to the unified interface(s) and data stored according to the unified data model into provider-specific call(s) with data formatted according to a provider-specific schema.
    Type: Application
    Filed: September 2, 2016
    Publication date: March 8, 2018
    Applicant: Microsoft Technology Licensing, LLC
    Inventors: Yuanji Wang, Ashok Srinivasan, Xuqing Zhang
  • Indazole compounds useful as ketohexokinase inhibitors
    Patent number: 9771375
    Abstract: The present invention is directed to substituted indazole compounds, pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X. In some embodiments, the substituted indazole compounds are of formula I, wherein R1-R3, Q, X, Y, Z, a, and b are defined herein.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: September 26, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Xuqing Zhang, Marta C Abad, Alan C. Gibbs, Gee-Hong Kuo, Fengbin Song, Zhihua Sui, Lawrence C. Kuo
  • TETRAHYDRO-BENZOIMIDAZOLYL MODULATORS OF TGR5
    Publication number: 20170029381
    Abstract: The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, X, Z1 and Z2 are defined in the specification.
    Type: Application
    Filed: April 14, 2015
    Publication date: February 2, 2017
    Inventors: Xuqing Zhang, Mark J. Wall, Zhihua Sui
  • Indole derivatives as selective androgen receptor modulators (SARMS)
    Patent number: 9434688
    Abstract: The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: September 6, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: James C Lanter, Zhihua Sui, James J Fiordeliso, Weiqin Jiang, Xuqing Zhang
  • Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
    Patent number: 9303037
    Abstract: The present invention is directed to novel tetracyclic heteroatom containing derivatives, pharmaceutical compositions containing them, their use in the treatment of disorders mediated by one or more sex steroid hormone receptors and processes for their preparation.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: April 5, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Zhihua Sui, Xuqing Zhang, Xiaojie Li
  • Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes
    Patent number: 9067898
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, G, and Q are defined herein.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: June 30, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Carl R. Illig, Mark R. Player, Xuqing Zhang
  • 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2
    Patent number: 8921559
    Abstract: The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, X, Y, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: December 30, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: James C. Lanter, Thomas P. Markotan, Nalin Subasinghe, Zhihua Sui, Xuqing Zhang
  • INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS
    Publication number: 20140336170
    Abstract: The present invention is directed to substituted indazole compounds, pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X.
    Type: Application
    Filed: July 23, 2014
    Publication date: November 13, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Xuqing Zhang, Marta C. Abad, Alan C. Gibbs, Gee-Hong Kuo, Fengbin Song, Zhihua Sui
  • GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
    Publication number: 20140275179
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows: wherein Y, R1, G, and Q are defined herein; and wherein R11, R21, R41, RB1 and G1, are defined herein.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 18, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Zhihua Sui, Chaozhong Cai, Xuqing Zhang
  • NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS)
    Publication number: 20140249197
    Abstract: The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
    Type: Application
    Filed: May 14, 2014
    Publication date: September 4, 2014
    Applicant: Janssen Pharmaceutica, NV
    Inventors: James C. Lanter, Zhihua Sui, James J. Fiordeliso, Weiqin Jiang, Xuqing Zhang
  • Indazole compounds useful as ketohexokinase inhibitors
    Patent number: 8822447
    Abstract: The present invention is directed to substituted indazole compounds of formula (I) pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: September 2, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Xuqing Zhang, Marta C. Abad, Alan C. Gibbs, Gee-Hong Kuo, Lawrence C. Kuo, Fengbin Song, Zhihua Sui
  • Indole derivatives as selective androgen receptor modulators (SARMS)
    Patent number: 8765782
    Abstract: The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: July 1, 2014
    Assignee: Janssen Pharmaceutica, NV
    Inventors: James C. Lanter, Zhihua Sui, James J. Fiordeliso, Weiqin Jiang, Xuqing Zhang
  • NOVEL TETRACYCLIC HETEROATOM CONTAINING DERIVATIVES USEFUL AS SEX STEROID HORMONE RECEPTOR MODULATORS
    Publication number: 20140066479
    Abstract: The present invention is directed to novel tetracyclic heteroatom containing derivatives, pharmaceutical compositions containing them, their use in the treatment of disorders mediated by one or more sex steroid hormone receptors and processes for their preparation.
    Type: Application
    Filed: November 11, 2013
    Publication date: March 6, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Zhihua Sui, Xuqing Zhang, Xiaojie Li
  • Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
    Patent number: 8580840
    Abstract: The present invention is directed to novel tetracyclic heteroatom containing derivatives, pharmaceutical compositions containing them, their use in the treatment of disorders mediated by one or more sex steroid hormone receptors and processes for their preparation.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: November 12, 2013
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Zhihua Sui, Xuqing Zhang, Xiaojie Li
  • 4-Azetidinyl-1-phenyl-cyclohexane antagonists of CCR2
    Patent number: 8513229
    Abstract: The present invention comprises compounds of Formula (I): wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: August 20, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Xuqing Zhang, Heather Rae Hufnagel, Cuifen Hou, Dana L. Johnson, Zhihua Sui
  • 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of CCR2
    Patent number: 8450304
    Abstract: The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, and R4 are as defined in the specification. The invention also comprises pharmaceutical compositions comprising the compounds of formula (I) and methods of preventing, treating or ameliorating a CCR2 mediated syndrome, disorder or disease, for example, type II diabetes, obesity or asthma, by administering the compounds of formula (I).
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: May 28, 2013
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Xuqing Zhang, Heather Rae Hufnagel, Cuifen Hou, Dana L. Johnson, Zhihua Sui, Barry Fegely, David Breslin
  • Cyclohexyl-azetidinyl antagonists of CCR2
    Patent number: 8436023
    Abstract: The present invention comprises compounds of Formula (I). wherein: R1, R2, X, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: May 7, 2013
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Xuqing Zhang, Zhihua Sui, James C. Lanter
  • Indole derivatives as selective androgen receptor modulators (SARMS)
    Patent number: 8394971
    Abstract: The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: March 12, 2013
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: James C. Lanter, Zhihua Sui, James J. Fiordeliso, Weiqin Jiang, Xuqing Zhang
  • 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of CCR2
    Patent number: 8324186
    Abstract: The present invention comprises compounds of Formula (I). wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: December 4, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Xuqing Zhang, Heather Rae Hufnagel, Zhihua Sui
  • Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
    Patent number: 8318766
    Abstract: The present invention is directed to novel tetracyclic heteroatom containing derivatives, pharmaceutical compositions containing them, their use in the treatment of disorders mediated by one or more sex steroid hormone receptors and processes for their preparation.
    Type: Grant
    Filed: February 2, 2010
    Date of Patent: November 27, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Zhihua Sui, Xuqing Zhang, Xiaojie Li